The present study evaluates the relationships between post-induction vedolizumab trough concentrations (VTC) and real-world outcomes in inflammatory bowel disease (IBD), including biomarkers of inflammation and clinical disease scores.
Aims & Methods
Participants in the Takeda Canada Patient Support Program who were treated with vedolizumab for Crohn’s disease (CD) and ulcerative colitis (UC) were assessed at defined timepoints from 2018-2020. Post-induction VTC (Week 14), baseline albumin (Week 0), faecal calprotectin (FC; Week 0 and 30), C-reactive protein (CRP; Week 0 and 30), Harvey-Bradshaw Index (HBI; Week 0 and 30) and Partial Mayo Scores (PMS; Week 0 and 30) were collected. Remission was defined by CRP (<5mg/L), FC (<250µg/g), HBI (<5), or PMS (<3) at Week 30. Receiver operating characteristic (ROC) curve analyses were used to measure the sensitivity, specificity, and optimal cut-point value of VTC for multiple definitions of remission. In multivariate analyses, covariates included optimal VTC threshold, age, sex, disease subtype, baseline albumin, disease duration, and biologic treatment exposure.